Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Immuron Ltd.
ClinicalTrials.gov Identifier:
NCT02316717
First received: November 6, 2014
Last updated: February 14, 2017
Last verified: February 2017

November 6, 2014
February 14, 2017
December 2014
October 2017   (Final data collection date for primary outcome measure)
  • Body Temperature [ Time Frame: 24 Weeks ]
    Changes in body temperature
  • Percentage Fat Content of the Liver [ Time Frame: 24 Weeks ]
    Mean change from Baseline in Percentage Fat Content of the Liver measured by Magnetic Resonance Imaging (MRI) at Week 24
  • Adverse Events [ Time Frame: 24 weeks ]
    Number of patients with adverse events
  • Adverse Events [ Time Frame: 24 weeks ]
    Severity of adverse events
  • Respiratory Rate [ Time Frame: 24 weeks ]
    Change in Respiratory Rate
  • Pulse Rate [ Time Frame: 24 weeks ]
    Change in Pulse Rate
  • Systolic Blood Pressure [ Time Frame: 24 weeks ]
    Change in Systolic Blood Pressure
  • Diastolic Blood Pressure [ Time Frame: 24 weeks ]
    Change in Diastolic Blood Pressure
  • Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis [ Time Frame: 24 weeks ]
    Change in Clinical Laboratory tests (Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis)
  • Serum Alanine Aminotransaminase (ALT) [ Time Frame: 24 weeks ]
    Mean change from Baseline in Serum Alanine Aminotransaminase (ALT) at Week 24
Same as current
Complete list of historical versions of study NCT02316717 on ClinicalTrials.gov Archive Site
  • Peak serum concentration (Cmax) [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Peak serum concentration (Cmax) of IMM-124E
  • Minimum serum concentration (Cmin) [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Minimum serum concentration (Cmin) of IMM-124E
  • Area Under the Concentration Time Curve (AUC) [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Area Under the Concentration Time Curve (AUC) of IMM-124E
  • Elimination Half Life (T1/2) [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Elimination Half Life (T1/2) of IMM-124E
  • Body Mass Index (BMI) [ Time Frame: 24 Weeks ]
    Change from Baseline of Body Mass Index (BMI) at 24 weeks
  • Waist Circumference [ Time Frame: 24 Weeks ]
    Change from Baseline of Waist Circumference at 24 weeks
  • Waist:Hip Ratio [ Time Frame: 24 Weeks ]
    Change from Baseline of Waist:Hip Ratio at 24 weeks
  • Hemoglobin (HB)A1C [ Time Frame: 24 Weeks ]
    Change from Baseline of Hemoglobin(HB)A1C at 24 weeks
  • Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [ Time Frame: 24 Weeks ]
    Change from Baseline of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 24 weeks
  • Total Cholesterol [ Time Frame: 24 Weeks ]
    Change from Baseline of Total Cholesterol at 24 weeks
  • Triglycerides [ Time Frame: 24 Weeks ]
    Change from Baseline of Triglycerides at 24 weeks
  • Low density lipoprotein (LDL) [ Time Frame: 24 Weeks ]
    Change from Baseline of Low Density Lipoprotein (LDL) at 24 weeks
  • High Density Lipoprotein (HDL) [ Time Frame: 24 Weeks ]
    Change from Baseline of High Density Lipoprotein (HDL) at 24 weeks
  • Serum Alanine Aminotransaminase (ALT) [ Time Frame: 0, 4, 8, 12, 16, 20 and 24 Weeks ]
    Mean change from Baseline of serum ALT
  • Serum Aspartate Aminotransaminase (AST) [ Time Frame: 0, 4, 8, 12, 16, 20 and 24 Weeks ]
    Mean change from Baseline of Serum AST
  • Bilirubin [ Time Frame: 0, 4, 8, 12, 16, 20 and 24 Weeks ]
    Mean change from Baseline of Bilirubin
  • Albumin [ Time Frame: 0, 4, 8, 12, 16, 20 and 24 Weeks ]
    Mean change from Baseline of Albumin
  • Gamma Glutamyl Transpeptidase (GGT) [ Time Frame: 0, 4, 8, 12, 16, 20 and 24 Weeks ]
    Mean change from Baseline of Gamma Glutamyl Transpeptidase (GGT)
  • Serum Alanine Aminotransaminase (ALT) [ Time Frame: 24 Weeks ]
    Number of patients with ALT within the normal reference range at Week 24(defined a <19 IU/L for women and <30 IU/L for men)
Same as current
  • Inflammatory Cytokines and other markers [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Serum Concentrations of Lipopolysaccharide (LPS), C-Reactive Protein (CRP), CK-18 fragments, C-peptide, Adiponectin and Cytokines IL6, IL12, IFN gamma and TNF alpha
  • Regulatory T cells in Peripheral Blood Mononuclear Cells [ Time Frame: 0, 12 and 24 Weeks ]
    Relative levels of Regulatory T cells in Peripheral Blood Mononuclear Cells
  • Gut Microbiome from Fecal Samples [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Characterization of the gut microbiome from fecal samples by DNA extraction and Bacterial ribosomal DNA amplification and sequencing
  • Gastrointestinal LPS levels [ Time Frame: 0, 4, 12 and 24 Weeks ]
    Gastrointestinal LPS levels from fecal samples
Same as current
 
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.
This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.

Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

Eligible subjects will be randomized at the Baseline visit to receive one of the three study treatments three times daily for a period of 24 weeks. Each subject will return to the study clinic for assessment and required study procedures on Day 7, 14 and 28 and every 4 weeks thereafter until Week 24.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Non-alcoholic Steatohepatitis (NASH)
  • Biological: IMM-124E
    IMM-124E
  • Other: Placebo
    Matched placebo
  • Experimental: Treatment Arm A
    IMM-124E, 600 mg three times daily, orally plus matching placebo
    Intervention: Biological: IMM-124E
  • Experimental: Treatment Arm B
    IMM-124E, 1200 mg three times daily, orally
    Intervention: Biological: IMM-124E
  • Placebo Comparator: Treatment Arm C
    Matching placebo, three times daily, orally
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
130
October 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Provision of written informed consent.
  3. Diagnosis of NASH, histologically proven within 12 months of Screening with

    • NASH activity score (NAS) of 4 or more
    • cytologic ballooning score of at least 1;
    • 10% or more macrovescicular steatosis.
    • Hematoxylin & Eosin (H&E) stained slides and/or paraffin block available for independent assessment.
  4. HBA1C of <9.0
  5. Agree to the use of effective contraceptive measures if either male or female of child bearing potential.

Exclusion Criteria:

  1. Presence of vascular liver disease or cirrhosis;
  2. Presence of liver disease with other cause (autoimmune, metabolic, medication induced);
  3. BMI <25 kg/m^2;
  4. Alcohol use >30 g/day;
  5. Type 1 diabetes;
  6. 6. History of major bariatric surgery (not including balloon / sleeve gastrectomy);
  7. Weight loss or gain of 5kg or more in the past 6 months or >10% change in bodyweight in the past 12 months;
  8. Contraindication for MRI;
  9. Inadequate venous access;
  10. Lactating/breastfeeding/pregnant at Screening or Baseline;
  11. HIV antibody positive, hepatitis B surface antigen positive (HBsAg) or Hepatitis C virus (HCV)-RNA positive;
  12. Receiving an elemental diet or parenteral nutrition;
  13. Concurrent conditions

    • Inflammatory bowel disease;
    • Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of Screening;
    • Ongoing infectious, ongoing multi-systemic immune-mediated and/or concurrent or past malignant disease;
    • Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or on the interpretation of the study data;
  14. Concurrent medications including:

    • anti-NASH therapy(s) taken for more than 10 continuous days in the last 3 months. These include S-adenosyl methionine (SAM-e), betaine, milk thistle, probiotic supplements (other than yoghurt), vitamin E and gemfibrozil.

      • NB: If vitamin E or gemfibrozil are used, the dose must be stable and liver biopsy confirming diagnosis of NASH subsequent to commencing treatment; commencing treatment;
      • Wash out for any of the anti-NASH therapies is as follows: under 10 days no washout required, more than 10 days and up to 3 months treatment requires 6 weeks washout. Any treatment of over 3 months would require to re-biopsy to ensure histological eligibility
    • thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or glucagon-like peptide-1 analogs in the last 6 months. If treatment commenced and is stable for more than 6 month prior to the determinant biopsy and the dose is still stable at time of study entry, subjects will be eligible for recruitment.
    • Allowable anti-diabetic treatment includes metformin and/or sulfonylureas administered at constant dose for at least 2 months prior to study entry.
    • Subjects treated with Insulin are eligible if clinically stable on insulin treatment (i.e. no recurrent acute hypo-/hyperglycemic episodes diagnosed clinically and by Glucose serum levels of <50 mg/dL and >200 mg/dL respectively) for at least 2 months prior to study entry.
    • immune modulatory agents including

      • In the last 3 months:
      • systemic steroids for more than 7 days.
      • daily treatment with multiple non-steroidal anti-inflammatory drugs (such as aspirin >100mg/day, ibuprofen, naproxen, meloxicam, celecoxib) for more than 1 month within 3 months prior to study entry;
      • In the last 12 months:
      • azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNFα therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies (namixilab) ;
    • more than 10 consecutive days oral or parenteral antibiotics within 4 weeks prior to study entry (Note: such subjects would not be included in the stool and PBMC analysis).
    • variable dose of antilipidemic agents (3-hydroxy-3-methyl-glutaryl (HMG)-Co-A reductase inhibitors - "statins") in the 3 months prior to study entry.
  15. The following laboratory abnormalities:

    • Neutrophil count ≤1.0 x 10^9/L
    • Platelets <100 x 10^9/L
    • Hemoglobin <10 g/dL
    • Albumin <3.5 g/dL
    • International Normalized Ratio (INR) >1.5
    • Total bilirubin >1.5 x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
    • Either creatinine clearance ≤60 mL/minute calculated by Cockroft Gault or creatinine >1.5x upper limit of reference range.
  16. Known substance abuse, including inhaled or injected drugs in the year prior to Screening.
  17. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to study products.
Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Israel
 
 
NCT02316717
IMM-124E-2001
No
Not Provided
Not Provided
Not Provided
Immuron Ltd.
Immuron Ltd.
Not Provided
Study Director: Dan Peres Immuron Ltd.
Immuron Ltd.
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP